Similar articles for PMID: 30389816

Year	Number of Results
2003	1
2005	1
2013	2
2015	7
2016	18
2017	27
2018	34
2019	48
2020	64
2021	91
2022	52
2023	16
2024	0

1

Dosimetry Estimate and Initial Clinical Experience with ⁹⁰Y-PSMA-617.

Rathke H, Flechsig P, Mier W, Bronzel M, Mavriopoulou E, Hohenfellner M, Giesel FL, Haberkorn U, Kratochwil C. Rathke H, et al. J Nucl Med. 2019 Jun;60(6):806-811. doi: 10.2967/jnumed.118.218917. Epub 2018 Nov 2. J Nucl Med. 2019. PMID: 30389816 Free article.

2

Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.

3

Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Violet J, et al. J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5. J Nucl Med. 2019. PMID: 30291192 Free article. Clinical Trial.

4

Examining Absorbed Doses of Indigenously Developed ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.

Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S. Kamaldeep, et al. Cancer Biother Radiopharm. 2021 Apr;36(3):292-304. doi: 10.1089/cbr.2020.3640. Epub 2020 May 5. Cancer Biother Radiopharm. 2021. PMID: 32379495

5

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.

Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, Stief C, Bartenstein P, Gratzke C, Lehner S, Rominger A. Fendler WP, et al. Oncotarget. 2017 Jan 10;8(2):3581-3590. doi: 10.18632/oncotarget.12240. Oncotarget. 2017. PMID: 27683041 Free PMC article.

6

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. Kratochwil C, et al. J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16. J Nucl Med. 2016. PMID: 26985056 Free article. Clinical Trial.

7

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.

8

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Heck MM, et al. Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22. Eur Urol. 2019. PMID: 30473431

9

Radiation Dosimetry for ¹⁷⁷Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M. Okamoto S, et al. J Nucl Med. 2017 Mar;58(3):445-450. doi: 10.2967/jnumed.116.178483. Epub 2016 Sep 22. J Nucl Med. 2017. PMID: 27660138 Free article.

10

Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.

Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G. Delker A, et al. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29. Eur J Nucl Med Mol Imaging. 2016. PMID: 26318602

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

298 results

Results by year